Ocrelizumab for treating primary progressive multiple sclerosis - guidance (TA585)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
12 June 2019

Abstract

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.

Is this guidance up to date?

Next review: 2022

Commercial arrangement

There is a simple discount patient access scheme and a commercial access agreement for ocrelizumab. Contact Welwyn.rx_bdop@roche.com for details.

Guidance development process

How we develop NICE technology appraisal guidance